Low price to sales ratios – Tailored Brands

This might sound obvious, but the most amount of income you can generate from a dollar of revenue is one dollar. Eventually taxes will kick in, and that will go down to a net profit margin of around 74%, depending on what province you live in. Then you add in expenses such as salaries, or cost of goods sold, or marketing, and that net margin goes lower. Finally, you have non-operational expenses such as financing which will bring the number even lower.

However, it all starts with revenues – if you can’t bring in anything on the top line, it is guaranteed that you won’t see anything flow to the bottom!

Which is why one of the periodic value screens I typically conduct are companies that have low price to sales ratios.

Most typically they trade that way because they are either in debt/solvency trouble, or in traditionally low margin industries (or both) – if your gross margins are 10%, you better be selling a lot of product in order to cover the other fixed expenses. It is one of the basic premises of my original CMA designation (now merged as CPA) to construct methods to judiciously track the linkage between the top line and the proper allocation of overhead expenses to different divisions.

However, if a company with relatively high top-line sales is not producing good financial results, there are value opportunities if one is lead to believe that management can tweak things to either induce higher profitability or to reduce fixed costs in a manner that will not endanger revenues. These results do not show up in historical financial statements, but when they do appear, the results can be very dramatic.

The most recent example of Francesca’s (Nasdaq: FRAN) fits the definition of dramatic:

FRAN has 3.06 million shares outstanding, so at the end of July they were about a $10 million market capitalization company. I’ll skip the bulk of their corporate history (they were one of those high-flyer retailers that caught tailwinds before they became like the next beanie baby), and their Q1-2020 result (note: their fiscal year ends January) was horrible – $87 million in sales, $9.7 million loss in operations. The trajectory looked like they were going into Chapter 11 (they did have some net cash on the balance sheet but not a ton).

Fast forward to Q2-2020, and a miracle happened – $106 million in sales, $1.4 million income from operations. The stock went haywire as you can see – especially given its low float. It’s very interesting to see when a company with 3 million shares outstanding has a day with 20 million shares traded in volume.

What’s interesting is some very smart people (or insider trading) edged the stock up a few days before the quarterly release. The day after Q2 was announced, the stock doubled and proceeded to wipe out the short sellers (on August 30, 2019 there were 1,163,624 shares that were short!).

Retail fashion is currently an industry that is getting killed because of a confluence of factors. There is the typical Amazon effect – most retailers are in malls, and malls have less traffic these days because people are discovering the experience is a pain in the ass. There are other transient factors, but in general the industry is taking it on the chin.

Reitmans (TSX: RET.A) is a good example. I can get a chart of their stock from October 2016, and place a ruler on my computer screen at a downward 30 degree slope, and it extrapolates to today.

Just because it is cheap doesn’t mean it is a good value – these cases can be classical value traps.

We move onto an interesting case, Tailored Brands:

Tailored Brands initially got on my radar a few months ago because it was on Michael Burry’s 13-F form. Burry is somebody that I have been aware of well before his “Big Short” days, specifically when he wrote on MSN Money at the turn of the millennium (his write-up on American Physician’s Capital was complete genius). Needless to say, I respect his thought process greatly. I was wonder what the heck he was thinking with TLRD, but I guessed the general thesis involved. He eventually explained some of his thinking in a 13-D filing indicating that he has been accumulating shares between $4.30 to $6.00.

Putting a long story short, his letter was that the company still makes money and if management believes in the business, they should scrap the dividend ($36 million a year) and instead buy back shares and increase the EPS materially.

This hype from Burry (who recently went public after a multi-year hiatus with an investment in Gamestop, another retailer, which I do not believe is a good decision because they are truly vulnerable to the Amazon effect) presumably got the short sellers in trouble (in the first week of September, there was an obvious spate of short covering – this is what happens when the stock goes up 40% in a short period of time!). Short interest is VERY high – 23.3 million shares as of August 30. The quarterly report is what got TLRD back down to earth again.

Looking at their financial statements, TLRD does look cheap from a price to sales perspective – annualizing the first 6 months, they sell $62 in revenues for every share outstanding. Operating income is still $91 million for the first half, although definitely going down.

The balance sheet isn’t great, but it is a manageable position – they have a large line of credit that extends out until April 2025 ($884 million outstanding), and a senior note ($229 million) which matures on July 2022. The senior notes trade around 99.5 cents on the dollar with a YTM of 7.2%. Right now the credit market does not look like it is locking out TLRD. Most of this debt acquired in the takeover of Joseph A. Banks (another clothing retailer) which was a total disaster. TLRD also has a large amount of lease liabilities, similar to other retailers, and more visible now due to IFRS 16.

In the last quarterly report, the company also listened to Burry and cut the dividend to zero, and made noise about buying back shares. This was actually a good sign.

When a company reduces its dividend to zero (a brave decision), in addition to the negative psychological sentiment associated with it, there is also the effect of having income funds dump the stock due to the investment policy, not to mention retail people that are deluded into believing the yield statistic they see on the stock is sustainable. There will be the technical effect of a lot of forced selling after the quarter, and I believe we are seeing it presently. The question is how many shares will get force-dumped, and when will the short sellers cover.

It is interesting how at one point the cost to short TLRD went as high as Beyond Meat for a few days – signs that borrowing is getting tougher.

Tailored Brands is mostly associated with the Men’s Warehouse brand, and in Canada it is Moore’s. The question is whether men’s fashions (suits and the like) is still subject to the Amazon steamroller. I would think this segment of retail fashion is less vulnerable than Reitman’s.

So the question is whether management is capable of clotting the bleeding. Guidance for the 3rd quarter was awful (sales down roughly 5%). Operationally management does appear to be getting into a better and more profitable niche (customization), and the question is whether they can pull it off competently.

The risks are pretty obvious. The situation can get worse. The operating income to debt ratio is quite high. Fashion is fickle, and I don’t even want to divulge on this website publicly the last time I bought a suit. That said, I think men’s fashions are less fickle than women’s, but if we get this much-anticipated recession or economic slowdown it will also not help the company’s financial fortunes – a suit is the last thing on the shopping list when one is worried about their employment (note: the Men’s Warehouse still made money during the 2008-2009 economic crisis).

That said, there was a pretty good reason why this thing was trading at $24/share a year ago. It could easily get there again – a couple quarterly reports with stabilization will do this. They set the bar very low for Q3. The CEO also put up $72k of his money into the stock after the quarterly report, which is better than nothing.

I’m buying shares in the low 4’s. It will not be a large position, but my price target is $20/share.

Normally I do not like these sorts of companies for a few reasons. One is that there are too many eyeballs tracking this, especially now that Burry has made his 13-D filing public. I am not typically a “follow Buffett” type of investor – usually when I read about something from another source, I use it as an exclusionary criterion. However, there is a good chance the market sentiment is so negative that the chances of a less negative outcome are a lot better than the consensus.

If it works out, I’ll buy a cheap suit.

Cost of shorting Beyond Meat

I received the following spam:

Instantly I thought… the hype is dropping off like what happened to the Beanie Babies – I’m guessing that consumer retail demand is probably starting to wane. Beyond Meat (Nasdaq: BYND)’s IPO lockup expires at the beginning of November and this is when another flood of shares will presumably hit the markets.

Beyond is trading at $148/share presently, or a market cap of $9 billion. This is a lot higher than it actually should be.

Unfortunately this revelation is not unique as there is a very large lineup of people that want to short this thing.

Even assuming I can get a borrow, if I were to short 100 shares of BYND at current market prices, I’d have to pay $88/day in interest expenses (another way of thinking about this – 88 cents per share per day!) in order to maintain the short!

Conversely if you believe for whatever reason this thing isn’t going down, you stand to make a fortune on raking in the borrow fees on the stock if you use the right broker.

What about options?

Using December as an example, a call option near-the-money (strike 145) is $8 at the midpoint, while a put option at the same strike is $31.40!

Even deeper in the money (e.g. strike price of $175) your break-even, even if you get a mid-point execution is $116/share, or basically paying a 22% premium to short the stock.

Even paying a spread (e.g. making a bet that BYND will be lower than $120/share by December expiration) by buying the 150 put and selling the 120, your effectively are paying $21.15 (again, assuming mid-point option trades) for a maximum $8.85 profit IF the stock goes to $120 or below in a few months.

This is one beyond expensive short sale!

Taking an investing break until after the election

So far, this has been a crappy quarter to date. Although thankfully it isn’t a quarter where I should have gone all-index (the S&P 500 is down ever so slightly), I really feel like I have badly unperformed – so far I’m underwater about 150bps or so, which is not a good feeling. My decision-making faculties have not been in focus. For the year, I’m still barely in the black, but my relative performance benchmark has been horrific. If I was an 8 cylinder engine, I’m firing on about 2 of them.

That said, I have sold off and cashed a lot of the portfolio and I will only start to consider re-deploying after the upcoming Canadian election. There will be a lot at stake, especially with respect to the oil and gas industry.

It is pretty evident by the non-presence of the Canadian government at the Trans-Mountain pipeline appeal that the incumbent Liberals are not really interested in seeing the project proceed – or at least they’re happy to stall it out. The six motions (concerning the second round of consultations with First Nations) received no evidence from the government – it seemed pretty likely that if the government did provide evidence, the appeal court would have likely struck down the appeal application.

So this is a pretty polarizing election. If the Conservatives don’t get a majority government, it is likely that status quo will continue – avoiding Western Canadian investments will generally be wise as Liberal governments tend to focus on Toronto and everything east of it (Bombardier, SNC Lavalin, etc.).

The oddsmakers at 338 right now are projecting a 70% chance that the Liberals will get the most seats, but this will undoubtedly change through the campaign. In 2015, at this point the NDP were leading polls nationally, but this changed pretty quickly!

In 2019 we have the following:

In other words – the campaign will matter. Those lines will shift trajectory as people start to dial in – I figure around mid to late September.

A comprehensive list of TSX Exchange Traded Debt

(Most recent post on this was September 4, 2020)

Over two years ago I lamented there was no good consolidated list of TSX-traded debentures available.

I’ll give Felix Choo some credit for resurrecting a digital version of this. In general, his lists are about half of the exchange traded debentures on the TSX.

After consolidating a bunch of information together and going through a hundred documents or so on SEDAR, I am finally in a position to publish an authoritative list of debentures (109) and notes (3) that are trading on the TSX.

I have not included TSX Venture, but in case if you were wondering what you were missing on the TSXV, only a handful – 22 tickers among 18 issuers. Maybe I’ll add them in the future.

The entire list (as of September 3, 2019) of TSX-listed debt instruments (convertible debentures, exchange-traded notes) can be accessed at the following shared Google Sheet linked here.

I’ll give the standard disclaimer: I have tried to make it very accurate, but things can slip through the cracks.

Other than trying to make this a “real-time” sheet (can anybody give me a good automated source of debenture quotations that doesn’t involve a $2,000/month Bloomberg Terminal?), comments to improve this would be appreciated.

Tax loss selling candidates, 2019

Below are 29 companies that are trading lower than 40% year to date on the TSX, that have a market cap of above $75 million. I’ve also restricted the share price to greater than 50 cents.

TSX tax loss candidates

August 30, 2019 closing prices
Last trade > $0.50
Market Cap > $75 million
YTD change -40% or worse
ItemSymbolNameSectorLastYTD %ChgMktCap ($M)
1TH-TTheratechnologiesBio4.98-40.14394
2AVCN-TAvicanna IncCannibis3.66-41.2588
3IDG-TIndigo Books & Music IncRetail6.6-41.49180
4BIR-TBirchcliff Energy LtdEnergy1.77-41.78503
5SOY-TSunopta IncFood3.07-41.86275
6SOX-TStuart Olson IncEngineering2.89-41.9782
7ATH-TAthabasca Oil CorpEnergy0.57-42.42303
8ADVZ-TAdvanz Pharma CorpBio14.7-42.93673
9CFX-TCanfor Pulp Products IncForestry9.08-43.99574
10UNS-TUni Select IncAuto10.79-44.41456
11MDF-TMediagrif InteracIT5.23-45.2981
12MPVD-TMountain Province DiamondsDiamonds1.04-46.67223
13HNL-THorizon North Logistics IncEnergy Service0.95-47.22155
14IMV-TImmunovaccine IncBio3.58-47.89186
15DII-B-TDorel Industries Inc Cl.B SvRetail Wholesale9.1-48.41292
16LGO-TLargo Resources LtdMetals1.37-51.59728
17PONY-TPainted Pony Energy LtdEnergy0.68-54.36114
18PEY-TPeyto ExplorationEnergy3.2-54.8554
19BNP-TBonavista Energy CorpEnergy0.54-55149
20DR-TMedical Facilities CorpHospitals6.74-55.19211
21NVA-TNuvista Energy LtdEnergy1.61-60.54370
22MAV-TMav Beauty Brands IncBeauty4.11-61.52155
23SNC-TSnc-Lavalin SvEngineering16.41-64.262,858
24OBE-TObsidian Energy LtdEnergy1.27-64.4397
25TRST-TCanntrust Holdings IncCannibis2.3-64.99335
26JE-TJust Energy Group IncEnergy Retail1.46-67.63227
27TRQ-TTurquoise Hill Resources LtdMetals0.58-74.221,187
28ZENA-TZenabis Global Inc.Cannibis1.06-82.33214
29PLI-TPrometic Life Sciences IncBio11.6-95.54280

Comments:

1: A bio company with an FDA approved small scale HIV medication (used in cases where mainline HIV treatments do not work), and a new product that is used for something called hard belly – which is a symptom in some long-term HIV patients as a side effect of the anti-retroviral drugs that they take to keep viral loads down. Stock is down because sales aren’t exactly going anywhere and those sales and marketing expenses are indeed quite high. Market cap is trading as if the company will get sold off (drug companies don’t capitalize their R&D expenses it takes to get a drug to market, so there is a bunch of hidden balance sheet value in the drugs, despite the relatively little revenues they get from them).

2, 25, 28: Are Marijuana companies, and I have no interest in analyzing them.

3: Indigo is a typical retail story. Their stock chart in the past 18 months is a straight line down. Aside from their lease commitments, their balance sheet isn’t in terrible shape and management has some time to decide what to do, but they are bleeding money at a frightening pace.

4, 7, 13, 17, 18, 19, 21, 24: Canadian oil/gas extraction companies, so I do not need to write further why they are trading down. 13 is an energy service company. My big surprise here is why there aren’t more companies on the down 40% list (doing some quick investigation, it is because most of them already got hammered in 2018 so the losses in 2019 relatively speaking isn’t as big).

5: A low margin food producer with a ton of debt on the balance sheet and bleeding cash. Not looking pretty.

6: Engineering firm impacted somewhat by oil and gas-related spending. Income statement shows they are treading water. They were able to raise financing from Canso at 7% for unsecured debt (rolling over an existing debt issue) and the balance sheet is not in terrible shape. May be a good possibility for a turnaround – given its market cap of $80 million in relation to its overall size (revenues will be roughly a billion in 2019), something to watch. Has a similar feel to IBI Group.

8: The old Concordia Pharma. Classic case of what happens when you over-leverage cash flows too much. They make a ton of cash, but they have a ton of debt and a ton of interest expenses.

9: Lumber has been killed for various reasons. Despite being from British Columbia, I should know more about the industry. Just a year ago it was trading at $27 and today it is nearly $9. The stock graph looks like a normal distribution curve. Despite the fact that their cash flows has been decimated year-to-year, they don’t have any debt and look like they can survive the cycle. Jimmy Pattison trying to take over Canfor Corporation (not the pulp subsidiary) for $16/share seems to be a case of trying to take them on the lows. Canfor owns 55% of Canfor Pulp.

10: I know less about automobile companies than forestry products. Skimming the financial statements, they just appear to be losing profitability and racking up debt.

11: A small IT firm that is undergoing a strategic change and also still looking for a new CEO. Still profitable, and with a relatively blank canvas balance sheet.

12: Owners of a 49% interest in a diamond mine in the N.W.T., and barely making enough to pay off their bank lenders. Will pass.

14: Early clinical stage biotech working on some cancer therapies, P2 studies have samples of less than 20 patients, and skimming the science, looks questionable.

15: Legitimate larger company that has been in a slow straight-line descent for the past three years. Three major product lines (babies, sports and furniture) are sold to major retailers worldwide. Management (Schwartz – family-controlled dual-stock corporation) has been around for a very long time, albeit they seem to be highly overpaid. They resolved an upcoming debt maturity last June with a 7.5% unsecured debt note (not convertible) and this will buy them time to figure out how to improve margins. Cash flows from operations have been diminishing, and they already once cut their dividend, and it is due for another cut. However, given the ~$300 market cap and $2.5 billion in revenues, the potential for a turnaround here is reasonably good, except for this looming worldwide recession coming which would surely impact this company’s fortunes!

16: They mine a commodity I know nothing about (Vanadium), in a country I know very little about (Brazil).

20: This one is interesting. A company that owns majority or near-majority stakes in a few hospitals in the USA and distributes most of its free cash. The only problem being that in the past few quarters, they have really underperformed. If they can figure out what they did wrong and reverse it, then the stock is an easy double from their depressed price. It was bond-like until the bottom fell out of it in the May and August quarterly reports. If there was a candidate for year-end tax loss selling, this one would be it. Another interesting quirk is that their distribution rate on a historical basis is now at a 17% yield. This distribution was below their cash generation in prior years, but not from the first half of this year. It’s likely they’ll cut this dividend unless if they think the past couple quarters was temporary. Knowing about the US healthcare industry, especially in the states that DR operates in, coupled with competitive dynamics of healthcare and competitors will help.

22: Cosmetics company that went public in July 2018 for CAD$14/share (proceeds to pay down debt with IPO). Now it is trading at $4.11/share, which is a fairly good 70% negative return on investment. The company is now barely profitable, but still isn’t at the level which supports the debt on its balance sheet. Still, cosmetics is a pretty high leverage industry to be in if your revenues start to take traction – and their revenues are growing. Might be interesting, considering that beauty products sell in any economic climate! Unfortunately, you won’t see me wearing any…

23: SNC. Enough said. There’s tons of industry analysts out there looking at this one. Their partial sale of the 407 freeway around Toronto will buy them a lot of time to get their act together, but in the meantime, their operations are a total mess. There will probably be a time to buy this one but it will take awhile, and likely more corruption from the federal government is required for a positive outcome (i.e. if Trudeau gets re-elected, it would be a positive for SNC for sure).

26: Balance sheet is a train wreck, company is exploring a recapitalization, and the business model itself is highly broken. Good luck!

27: Another mining company working in a jurisdiction I know hardly anything about (Mongolia), let alone I can’t even pronounce the name of its main flagship mine. Don’t have any more insight than that, sadly.

28: The big loser in the TSX is due to a debt-to-equity recapitalization and a 1:1000 reverse stock split. After the recap they did get rid of a bunch of debt on the balance sheet and raised some cash, which they need in order to bide their time to get FDA approval for their lead product. They burnt about $50 million cash in the first half of the year and have about $80 million left on the balance sheet, so looks like they’ll have to raise more financing…